Eleven Biotherapeutics (EBIO) Upgraded to Sell at ValuEngine
Eleven Biotherapeutics (NASDAQ:EBIO) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.
Eleven Biotherapeutics (NASDAQ EBIO) opened at $0.95 on Friday. Eleven Biotherapeutics has a 1 year low of $0.62 and a 1 year high of $2.54. The company has a market cap of $30.36, a P/E ratio of -0.90 and a beta of 3.04.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Monday, November 20th. The biopharmaceutical company reported ($0.37) EPS for the quarter.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.